Published in Exp Hematol on December 01, 1995
Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol (2003) 1.86
Early recurrence or persistence of autoimmune diseases after unmanipulated autologous stem cell transplantation. Blood (1996) 1.70
High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. J Clin Oncol (2004) 1.70
Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia (2005) 1.60
Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood (1997) 1.59
Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects. Ann Oncol (2005) 1.58
The fluctuating phenotype of the lymphohematopoietic stem cell with cell cycle transit. J Exp Med (1998) 1.57
Studies of the RB1 gene and the p53 gene in human osteosarcomas. Pediatr Hematol Oncol (1992) 1.57
The molecular defects of alpha-thalassemia in the Filipino. Hemoglobin (1977) 1.47
Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma. Leukemia (2004) 1.45
Specificity of reverse transcriptase polymerase chain reaction assays designed for the detection of circulating cancer cells is influenced by cytokines in vivo and in vitro. Br J Cancer (1998) 1.42
Pharmacokinetics of undiluted or diluted high-dose etoposide with or without busulfan administered to patients with hematologic malignancies. J Clin Oncol (1994) 1.40
Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol (1988) 1.39
Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia. Leukemia (2011) 1.24
Detection of micrometastasis by cytokeratin 20 RT-PCR is limited due to stable background transcription in granulocytes. Br J Cancer (1999) 1.24
EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT. Bone Marrow Transplant (2008) 1.17
Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93. J Clin Oncol (2001) 1.15
Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells. Bone Marrow Transplant (2009) 1.14
Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program. Bone Marrow Transplant (2010) 1.14
Stem cell transplantation in the normal nonmyeloablated host: relationship between cell dose, schedule, and engraftment. Exp Hematol (1997) 1.12
CD34 splice variant: an attractive marker for selection of gene-modified cells. Mol Ther (2000) 1.10
Assessment of iron stores in children with transfusion siderosis by biomagnetic liver susceptometry. Am J Hematol (1999) 1.09
Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up. Bone Marrow Transplant (2006) 1.09
Early infections in patients undergoing bone marrow or blood stem cell transplantation--a 7 year single centre investigation of 409 cases. Bone Marrow Transplant (1999) 1.08
Emergence of linezolid resistance in a methicillin resistant Staphylococcus aureus strain. Infection (2007) 1.08
Fetal and adult liver stem cells for liver regeneration and tissue engineering. J Cell Mol Med (2006) 1.07
Hepatocytic gene expression in cultured rat mesenchymal stem cells. Transplant Proc (2005) 1.05
Current options in treatment of anthracycline-resistant breast cancer. Cancer Treat Rev (1999) 1.04
Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia. Leukemia (1997) 1.03
Interference of cytokeratin-20 and mammaglobin-reverse-transcriptase polymerase chain assays designed for the detection of disseminated cancer cells. Med Oncol (2001) 1.03
Engraftment of bone marrow cells into normal unprepared hosts: effects of 5-fluorouracil and cell cycle status. Blood (1995) 1.03
Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Ann Hematol (2003) 1.03
Serum ferritin iron in iron overload and liver damage: correlation to body iron stores and diagnostic relevance. J Lab Clin Med (2000) 1.03
Cognitive function in the acute course of allogeneic hematopoietic stem cell transplantation for hematological malignancies. Bone Marrow Transplant (2007) 1.02
Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias. Leukemia (2003) 1.01
High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease. Ann Intern Med (1986) 1.00
Reverse transcriptase/polymerase chain reaction detection of cytokeratin-19 mRNA in bone marrow and blood of breast cancer patients. J Cancer Res Clin Oncol (1996) 1.00
In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors. Bone Marrow Transplant (2002) 0.99
High levels of engraftment with a single infusion of bone marrow cells into normal unprepared mice. Biol Blood Marrow Transplant (1995) 0.99
Improved treatment results in childhood acute myelogenous leukemia: a report of the German cooperative study AML-BFM-78. Blood (1985) 0.99
Phenotype of lymphocyte subsets after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant (1997) 0.98
Comparable results in patients with acute lymphoblastic leukemia after related and unrelated stem cell transplantation. Bone Marrow Transplant (2006) 0.96
Improved outcome in haemophagocytic lymphohistiocytosis after bone marrow transplantation from related and unrelated donors: a single-centre experience of 12 patients. Br J Haematol (1999) 0.96
Soluble interleukin-2 receptor serum levels after allogeneic bone marrow transplantations as a marker for GVHD. Bone Marrow Transplant (1998) 0.95
Amphotropic murine leukemia viruses induce spongiform encephalomyelopathy. Proc Natl Acad Sci U S A (1997) 0.95
Infectious risks of Broviac catheters in children with neoplastic diseases: a matched pairs analysis. Pediatr Infect Dis J (1992) 0.95
Efficient depletion of alloreactive donor T lymphocytes based on expression of two activation-induced antigens (CD25 and CD69). Br J Haematol (2000) 0.94
Comparison of the content and subpopulations of CD3 and CD34 positive cells in bone marrow harvests and G-CSF-mobilized peripheral blood leukapheresis products from healthy adult donors. Transpl Immunol (1996) 0.94
The role of biomedical and psychosocial factors for the prediction of pain and distress in patients undergoing high-dose therapy and BMT/PBSCT. Bone Marrow Transplant (2002) 0.93
High-dose multidrug resistance in primary human hematopoietic progenitor cells transduced with optimized retroviral vectors. Blood (1996) 0.92
Busulfan, cyclophosphamide and etoposide as high-dose conditioning therapy in patients with malignant lymphoma and prior dose-limiting radiation therapy. Bone Marrow Transplant (1998) 0.92
Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis. Ann Rheum Dis (2003) 0.92
Cytokine-facilitated transduction leads to low-level engraftment in nonablated hosts. Blood (1997) 0.91
Cyclic neutropenia and T lymphocyte suppression of granulopoiesis: abrogation of the neutropenic cycles by lithium carbonate. Leuk Res (1982) 0.91
Impaired plasma antioxidative defense and increased nontransferrin-bound iron during high-dose chemotherapy and radiochemotherapy preceding bone marrow transplantation. Free Radic Biol Med (2000) 0.91
Real-time quantitative Y chromosome-specific PCR (QYCS-PCR) for monitoring hematopoietic chimerism after sex-mismatched allogeneic stem cell transplantation. J Hematother Stem Cell Res (2001) 0.91
Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients. Bone Marrow Transplant (2001) 0.90
Aldehyde dehydrogenase activity as a marker for the quality of hematopoietic stem cell transplants. Bone Marrow Transplant (2005) 0.90
Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic-SCT. Bone Marrow Transplant (2010) 0.90
A novel 'sort-suicide' fusion gene vector for T cell manipulation. Gene Ther (2002) 0.90
MRD at the end of induction therapy in childhood acute lymphoblastic leukemia: outcome prediction strongly depends on the therapeutic regimen. Leukemia (2001) 0.90
Microregional distributions of glucose, lactate, ATP and tissue pH in experimental tumours upon local hyperthermia and/or hyperglycaemia. J Cancer Res Clin Oncol (1993) 0.90
Prostaglandin E1-mediated augmentation of human granulocyte-macrophage progenitor cell growth in vitro. Leuk Res (1981) 0.90
T lymphocyte and monocyte-macrophage interaction in colony-stimulating activity elaboration in man. Blood (1979) 0.89
Adjuvant chemotherapy in osteosarcoma - effects of cisplatinum, BCD, and fibroblast interferon in sequential combination with HD-MTX and adriamycin. Preliminary results of the COSS 80 study. J Cancer Res Clin Oncol (1983) 0.89
[Malignant melanoma of the anorectal mucosa]. Dtsch Med Wochenschr (2004) 0.88
In vitro culture studies of childhood myelodysplastic syndrome: establishment of the cell line MUTZ-1. Leuk Lymphoma (1997) 0.88
[Labeling of mesenchymal stem cells with different superparamagnetic particles of iron oxide and detectability with MRI at 3T]. Rofo (2005) 0.88
Diurnal changes in circulating myeloid progenitor cells in man. Am J Hematol (1980) 0.88
Practices of infectious disease prevention and management during hematopoietic stem cell transplantation: a survey from the European group for blood and marrow transplantation. J Hematother Stem Cell Res (2001) 0.88